

Donanemab: A New Ray of Hope in the Fight Against Alzheimer's
7 snips May 11, 2023
The podcast discusses a new drug called Donanemab that shows promise in treating Alzheimer's disease by targeting the amyloid-beta protein. Challenges include cost and long-term effects. Other topics include the role of tau protein, the self-correcting nature of science, the importance of lifestyle factors, exercise and sleep, and addressing risk factors for Alzheimer's.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Introduction
00:00 • 2min
Eli Lilly's Donanemab: A New Alzheimer's Drug
02:21 • 16min
Understanding the Role of Tau Protein in Alzheimer's Disease
18:42 • 3min
Embracing Nuance and the Self-Correcting Nature of Science
22:06 • 2min
The Importance of Lifestyle Factors for Alzheimer's Prevention
24:09 • 14min
Exercise, Sleep, and Cognitive Resilience
38:24 • 7min
Addressing Risk Factors for Alzheimer's Disease in Midlife and Beyond
45:28 • 3min